Holen Sie sich die Stockscreener-App
24.95
4.78%
1.0992
Schlusskurs vom Vortag:
$23.85
Offen:
$24.47
24-Stunden-Volumen:
15.47M
Relative Volume:
0.45
Marktkapitalisierung:
$5.78B
Einnahmen:
$2.35B
Nettoeinkommen (Verlust:
$128.37M
KGV:
47.79
EPS:
0.5221
Netto-Cashflow:
$57.42M
1W Leistung:
+8.46%
1M Leistung:
-14.97%
6M Leistung:
-34.92%
1J Leistung:
-53.17%
1-Tages-Spanne:
$24.24
$25.78
1-Wochen-Bereich:
$22.61
$25.78
52-Wochen-Spanne:
$13.74
$70.43
Hims Hers Health Inc Stock (HIMS) Company Profile
Firmenname
Hims Hers Health Inc
Sektor
Telefon
415-851-0195
Adresse
2269 CHESTNUT ST, SAN FRANCISCO
Compare HIMS vs TAK, HLN, TEVA, ZTS, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HIMS
Hims Hers Health Inc
|
24.95 | 5.52B | 2.35B | 128.37M | 57.42M | 0.5221 |
TAK
Takeda Pharmaceutical Co Adr
|
16.18 | 50.14B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.295 | 40.92B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.58 | 40.30B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
79.53 | 33.63B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
576.03 | 24.55B | 3.17B | 1.29B | 1.01B | 27.09 |
Hims Hers Health Inc Stock (HIMS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-24 | Eingeleitet | JP Morgan | Overweight |
| 2026-03-10 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2026-03-10 | Hochstufung | Citigroup | Sell → Neutral |
| 2026-03-09 | Hochstufung | Needham | Hold → Buy |
| 2026-02-24 | Herabstufung | BTIG Research | Buy → Neutral |
| 2026-01-12 | Eingeleitet | Evercore ISI | In-line |
| 2025-12-09 | Eingeleitet | Barclays | Overweight |
| 2025-10-21 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2025-06-23 | Herabstufung | Needham | Buy → Hold |
| 2025-06-04 | Bestätigt | Needham | Buy |
| 2025-04-29 | Herabstufung | TD Cowen | Buy → Hold |
| 2025-02-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-01-10 | Herabstufung | Citigroup | Neutral → Sell |
| 2025-01-07 | Eingeleitet | BTIG Research | Buy |
| 2024-12-17 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-11-14 | Herabstufung | BofA Securities | Buy → Underperform |
| 2024-08-22 | Eingeleitet | Needham | Buy |
| 2024-08-09 | Herabstufung | Imperial Capital | Outperform → In-line |
| 2024-05-22 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-04-16 | Herabstufung | Jefferies | Buy → Hold |
| 2024-04-10 | Eingeleitet | Canaccord Genuity | Buy |
| 2024-02-28 | Hochstufung | Imperial Capital | In-line → Outperform |
| 2024-02-26 | Eingeleitet | Leerink Partners | Market Perform |
| 2023-12-07 | Eingeleitet | Imperial Capital | In-line |
| 2023-07-28 | Eingeleitet | TD Cowen | Outperform |
| 2023-04-11 | Eingeleitet | Robert W. Baird | Neutral |
| 2023-02-09 | Hochstufung | Jefferies | Hold → Buy |
| 2022-11-08 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-11-08 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-10-17 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-09-07 | Eingeleitet | Truist | Hold |
| 2022-07-15 | Eingeleitet | SVB Leerink | Underperform |
| 2022-04-14 | Eingeleitet | Guggenheim | Buy |
| 2022-04-01 | Fortgesetzt | Credit Suisse | Outperform |
| 2022-03-10 | Eingeleitet | Deutsche Bank | Hold |
| 2021-12-02 | Eingeleitet | Jefferies | Hold |
| 2021-11-11 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-07-06 | Eingeleitet | BofA Securities | Neutral |
| 2021-05-20 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2021-04-21 | Eingeleitet | Truist | Hold |
| 2021-03-09 | Eingeleitet | Credit Suisse | Neutral |
| 2021-03-02 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-02-17 | Eingeleitet | Citigroup | Neutral |
| 2021-02-12 | Eingeleitet | Piper Sandler | Neutral |
| 2021-02-08 | Eingeleitet | Tigress Financial | Buy |
Alle ansehen
Hims Hers Health Inc Aktie (HIMS) Neueste Nachrichten
Hims & Hers stock rises after insider buy (HIMS:NYSE) - Seeking Alpha
Hims Insider Makes First Stock Purchase Since 2021 Amid Weight-Loss Drug Pivot - Barron's
Hims & Hers Shares Rally On Million-Dollar Insider Purchase - Benzinga
Why is Hims & Hers Health stock rallying today? By Investing.com - Investing.com Canada
Can Hims & Hers (HIMS) Canadian GLP-1 Push Redefine Its Long-Term Profitability Playbook? - simplywall.st
HIMS stock heads for weekly loss — but ex-Netflix CFO is buying the dip despite BofA’s GLP-1 warning - MSN
HIMS Stock Heads For Weekly Loss — But Ex-Netflix CFO Is Buying The Dip Despite BofA’s GLP-1 Warning - Stocktwits
Hims & Hers Health stock rises as director buys shares - Investing.com
Hims & Hers Health stock rises as director buys shares By Investing.com - Investing.com Nigeria
Hims & Hers faces steep climb to hit 2026 guidance as Wegovy churn risk looms, says BofA - Proactive financial news
HIMS stock extends 3-day rally: Hims & Hers targets GLP-1 gold rush in Canada after Novo Nordisk patent expiry - MSN
Hims & Hers Health, Inc. Stock 12‑Month Price Target Cut to $27.71, Implies 17% Upside - TradingView
Hims & Hers Stock Jumped 6.6% This Week. Here’s What a $350 Million Capital Raise for Growth - TIKR.com
Here is What to Know Beyond Why Hims & Hers Health, Inc. (HIMS) is a Trending Stock - Yahoo Finance
BofA cuts Hims and Hers stock price target on GLP-1 ramp concerns - Investing.com Canada
Modest pullback for Hims & Hers Health stock as oversold signals emerge - Traders Union
$Hims & Hers Health (HIMS.US)$ Should i cut loss now[Sob]im almost enough with this - Moomoo
10 Health Care Stocks With Whale Alerts In Today's Session - Benzinga
Four telehealth platforms now offer generic semaglutide - Benefits and Pensions Monitor
Hims & Hers Health stock price forecast: $22.50 support as HIMS trades down - Traders Union
(HIMS) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
How The Hims & Hers Health (HIMS) Story Is Shifting With GLP‑1 Hopes And Margin Questions - Yahoo Finance
Hims & Hers Health (HIMS) Stock Forum and Discussion - Moomoo
HIMS stock slips overnight: Hims & Hers bulks up debt raise to $350M for Eucalyptus buyout, AI push - MSN
Hims & Hers Health Inc. Class A (HIMS) Stock Price | Live Quotes & Charts | NYSE - StocksToTrade
Hims & Hers Health Options Spot-On: On May 22nd, 109.56K Contracts Were Traded, With 1.05 Million Open Interest - Moomoo
Hims & Hers (HIMS) CMO-director gets 435 RSUs instead of $10K cash retainer - Stock Titan
Hims & Hers (HIMS) director Christopher Payne awarded 647 RSUs for Q1 2026 fees - Stock Titan
Hims & Hers Health (HIMS) director awarded 957 RSUs for Q1 fees - Stock Titan
Latham Advises on Hims & Hers Health, Inc.’s Upsized US$350 Million Convertible Senior Notes Offering - Latham & Watkins LLP
HIMS Maintained by Truist Securities -- Price Target Raised to $23 - GuruFocus
Hims & Hers Deepens Personalized Care Through Platform Expansion - TradingView
Hims & Hers Has Fallen 66% From Its Peak. Does the $350M Debt Raise Signal a Turning Point or a Red Flag? - TIKR.com
Truist Financial Maintains Hims & Hers Health(HIMS.US) With Hold Rating - Moomoo
Truist raises Hims and Hers stock price target on GLP-1 insights - Investing.com
Hims & Hers Health, Inc. Announces Issuance of 0.00% Convertible Senior Notes Due 2032 and Indenture with U.S. Bank Trust Company - Minichart
HIMS Stock Price, Quote & Chart | HIMS & HERS HEALTH INC (NYSE:HIMS) - ChartMill
HIMS Stock Extends 3-Day Rally: Hims & Hers Targets GLP-1 Gold Rush In Canada After Novo Nordisk Patent Expiry - Yahoo Finance
Hims & Hers Health Inc (HIMS) Stock Up 4.2% and Still Undervalued -- GF Score: 77/100 - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Is Investigating Hims & Hers H - The National Law Review
Hims & Hers Health issues $402.5 million in convertible senior notes due 2032 - Investing.com
Hims & Hers Health Raises $402.5 Million Via 0% Convertible Notes; Adds Capped Calls at $50.15 Cap - TradingView
Hims & Hers (NYSE: HIMS) issues $402.5M 2032 zero-coupon convertibles - Stock Titan
Hims & Hers stock gains on Canada GLP-1 launch By Investing.com - Investing.com Nigeria
Hims & Hers stock gains on Canada GLP-1 launch - Investing.com
Canadians can now get digital prescriptions for 'generic Ozempic' - Financial Post
Hims offers Apotex's generic semaglutide in Canada after Novo patent expiry - Reuters
The Silver Lining of Last Week's Hims & Hers Earnings Miss - MarketBeat
Is Hims and Hers Health Stock a Buy After Its Latest Dip? - AOL.com
HIMS Launches Generic Semaglutide in Canada - GuruFocus
Why Hims & Hers Health Stock Just Crashed - AOL.com
Finanzdaten der Hims Hers Health Inc-Aktie (HIMS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.18%
0.28%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):